Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors during the central nervous process, conolidine modulates alternate molecular targets. A Science Innovations review found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, … Read More

Elucidating the precise pharmacological system of action (MOA) of naturally developing compounds is usually complicated. Even though Tarselli et al. (sixty) developed the first de novo artificial pathway to conolidine and showcased this naturally happening compound correctly suppresses responses to equally chemically induced and inflammation-derive… Read More